{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.2","value":"71.3"},{"groupId":"OG001","spread":"21.4","value":"72.7"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.4","value":"73.4"},{"groupId":"OG001","spread":"19.5","value":"76.2"}]}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.5","value":"71.1"},{"groupId":"OG001","spread":"20.5","value":"76.9"}]}],"title":"Week 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.7","value":"72.0"},{"groupId":"OG001","spread":"20.2","value":"76.7"}]}],"title":"Week 26/Early Withdrawal"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"Health-related quality of life (HR-QoL) patient reported outcomes from the motivation and energy inventory-short form (MEI-SF) questionnaire. Scores could range from 0 (worst possible) to 72 (best possible).","dispersionType":"Standard Deviation","groups":[{"description":"Matching placebo tablets taken once a day","id":"OG000","title":"Placebo"},{"description":"Eltrombopag 50 mg oral tablets taken once a day (QD)","id":"OG001","title":"Eltrombopag 50 mg QD"}],"paramType":"MEAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Baseline, Week 6, Week 14, and Week 26/Early Withdrawal","title":"HR-QoL Instrument and Domain Scores From the MEI-SF Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment","type":"SECONDARY","unitOfMeasure":"Points on a scale (0-72)"}